View in EDS HTML Full Text PDF Full Text

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
Authors: Anywaine Z; Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Barry H; Centre MURAZ, Bobo-Dioulasso, Burkina Faso., Anzala O; KAVI - Institute of Clinical Research University of Nairobi, Nairobi, Kenya., Mutua G; KAVI - Institute of Clinical Research University of Nairobi, Nairobi, Kenya., Sirima SB; Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Unité de Recherche Clinique de Banfora, Banfora, Burkina Faso., Eholie S; Unit of Infectious and Tropical Diseases, BPV3, Treichville University Teaching Hospital, Abidjan, Côte d'Ivoire., Kibuuka H; Makerere University - Walter Reed Project, Kampala, Uganda., Bétard C; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France., Richert L; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.; Vaccine Research Institute (VRI), Créteil, France., Lacabaratz C; Vaccine Research Institute (VRI), Créteil, France.; Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Shukarev G; Janssen Vaccines and Prevention, Leiden, the Netherlands., Katwere M; Janssen Vaccines and Prevention, Leiden, the Netherlands., Robinson C; Janssen Vaccines and Prevention, Leiden, the Netherlands., Gaddah A; Janssen Research & Development, Beerse, Belgium., Heerwegh D; Janssen Research & Development, Beerse, Belgium., Bockstal V; Janssen Vaccines and Prevention, Leiden, the Netherlands., Luhn K; Janssen Vaccines and Prevention, Leiden, the Netherlands., Leyssen M; Janssen Vaccines and Prevention, Leiden, the Netherlands., Thiébaut R; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.; Vaccine Research Institute (VRI), Créteil, France., Douoguih M; Janssen Vaccines and Prevention, Leiden, the Netherlands.
Corporate Authors: EBL2002 Study group
Source: PLoS medicine [PLoS Med] 2022 Jan 11; Vol. 19 (1), pp. e1003865. Date of Electronic Publication: 2022 Jan 11 (Print Publication: 2022).
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35015777
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Anywaine+Z%22">Anywaine Z</searchLink>; Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.<br /><searchLink fieldCode="AU" term="%22Barry+H%22">Barry H</searchLink>; Centre MURAZ, Bobo-Dioulasso, Burkina Faso.<br /><searchLink fieldCode="AU" term="%22Anzala+O%22">Anzala O</searchLink>; KAVI - Institute of Clinical Research University of Nairobi, Nairobi, Kenya.<br /><searchLink fieldCode="AU" term="%22Mutua+G%22">Mutua G</searchLink>; KAVI - Institute of Clinical Research University of Nairobi, Nairobi, Kenya.<br /><searchLink fieldCode="AU" term="%22Sirima+SB%22">Sirima SB</searchLink>; Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Unité de Recherche Clinique de Banfora, Banfora, Burkina Faso.<br /><searchLink fieldCode="AU" term="%22Eholie+S%22">Eholie S</searchLink>; Unit of Infectious and Tropical Diseases, BPV3, Treichville University Teaching Hospital, Abidjan, Côte d'Ivoire.<br /><searchLink fieldCode="AU" term="%22Kibuuka+H%22">Kibuuka H</searchLink>; Makerere University - Walter Reed Project, Kampala, Uganda.<br /><searchLink fieldCode="AU" term="%22Bétard+C%22">Bétard C</searchLink>; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Richert+L%22">Richert L</searchLink>; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.; Vaccine Research Institute (VRI), Créteil, France.<br /><searchLink fieldCode="AU" term="%22Lacabaratz+C%22">Lacabaratz C</searchLink>; Vaccine Research Institute (VRI), Créteil, France.; Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France.<br /><searchLink fieldCode="AU" term="%22McElrath+MJ%22">McElrath MJ</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.<br /><searchLink fieldCode="AU" term="%22De+Rosa+SC%22">De Rosa SC</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.<br /><searchLink fieldCode="AU" term="%22Cohen+KW%22">Cohen KW</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.<br /><searchLink fieldCode="AU" term="%22Shukarev+G%22">Shukarev G</searchLink>; Janssen Vaccines and Prevention, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Katwere+M%22">Katwere M</searchLink>; Janssen Vaccines and Prevention, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Robinson+C%22">Robinson C</searchLink>; Janssen Vaccines and Prevention, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Gaddah+A%22">Gaddah A</searchLink>; Janssen Research & Development, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Heerwegh+D%22">Heerwegh D</searchLink>; Janssen Research & Development, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Bockstal+V%22">Bockstal V</searchLink>; Janssen Vaccines and Prevention, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Luhn+K%22">Luhn K</searchLink>; Janssen Vaccines and Prevention, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Leyssen+M%22">Leyssen M</searchLink>; Janssen Vaccines and Prevention, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Thiébaut+R%22">Thiébaut R</searchLink>; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.; Vaccine Research Institute (VRI), Créteil, France.<br /><searchLink fieldCode="AU" term="%22Douoguih+M%22">Douoguih M</searchLink>; Janssen Vaccines and Prevention, Leiden, the Netherlands.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22EBL2002+Study+group%22">EBL2002 Study group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101231360%22">PLoS medicine</searchLink> [PLoS Med] 2022 Jan 11; Vol. 19 (1), pp. e1003865. <i>Date of Electronic Publication: </i>2022 Jan 11 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101231360 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-1676 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215491277%22">15491277 </searchLink><i>NLM ISO Abbreviation: </i>PLoS Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35015777
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1371/journal.pmed.1003865
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e1003865
    Titles:
      – TitleFull: Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Anywaine Z
      – PersonEntity:
          Name:
            NameFull: Barry H
      – PersonEntity:
          Name:
            NameFull: Anzala O
      – PersonEntity:
          Name:
            NameFull: Mutua G
      – PersonEntity:
          Name:
            NameFull: Sirima SB
      – PersonEntity:
          Name:
            NameFull: Eholie S
      – PersonEntity:
          Name:
            NameFull: Kibuuka H
      – PersonEntity:
          Name:
            NameFull: Bétard C
      – PersonEntity:
          Name:
            NameFull: Richert L
      – PersonEntity:
          Name:
            NameFull: Lacabaratz C
      – PersonEntity:
          Name:
            NameFull: McElrath MJ
      – PersonEntity:
          Name:
            NameFull: De Rosa SC
      – PersonEntity:
          Name:
            NameFull: Cohen KW
      – PersonEntity:
          Name:
            NameFull: Shukarev G
      – PersonEntity:
          Name:
            NameFull: Katwere M
      – PersonEntity:
          Name:
            NameFull: Robinson C
      – PersonEntity:
          Name:
            NameFull: Gaddah A
      – PersonEntity:
          Name:
            NameFull: Heerwegh D
      – PersonEntity:
          Name:
            NameFull: Bockstal V
      – PersonEntity:
          Name:
            NameFull: Luhn K
      – PersonEntity:
          Name:
            NameFull: Leyssen M
      – PersonEntity:
          Name:
            NameFull: Thiébaut R
      – PersonEntity:
          Name:
            NameFull: Douoguih M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 01
              Text: 2022 Jan 11
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1549-1676
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: PLoS medicine
              Type: main
ResultId 1